Showing results (331-340 of 344) with videos related to

Sort By:
Pageof 35
Haematologica|April 30, 2025
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patientsGregorio Barilà, Angela Grassi, Concetta Conticello, et al.
Hematological Oncology|February 3, 2025
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World StudyEnrica Antonia Martino, Daniele Derudas, Elena Rossi, et al.
Frontiers in Oncology|August 4, 2022
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical TrialsFortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Frontiers in Oncology|September 13, 2021
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA NetworkGiorgina Specchia, Patrizia Pregno, Massimo Breccia, et al.
Haematologica|July 13, 2023
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trialsMassimo Gentile, Ernesto Vigna, Salvatore Palmieri, et al.
Blood|December 27, 2019
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML studySimona Soverini, Luana Bavaro, Caterina De Benedittis, et al.
Hematological Oncology|May 31, 2024
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trialsEnrica Antonia Martino, Salvatore Palmieri, Monica Galli, et al.
European Journal of Haematology|December 30, 2020
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia casesFortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, et al.
Cancer Medicine|September 24, 2020
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US studyAntonio Cuneo, Anthony R Mato, Gian Matteo Rigolin, et al.
Hematological Oncology|May 24, 2022
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trialsAntonella Bruzzese, Daniele Derudas, Monica Galli, et al.
Pageof 35